You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.
The firms will have exclusive access for a limited time to the data from the first 50,000 individuals with samples in the biobank to be sequenced.
The study seeks to identify biomarkers that can help personalize treatment for patients by identifying signs of rapid decline in kidney function.
GlaxoSmithKline and Verily Life Sciences form Galvani Bioelectronics.
Drug developers and genetic testing firms are contemplating how best to share variant classification data while protecting their commercial interests.
Five people have been indicted for stealing trade secrets from GlaxoSmithKline, the Wall Street Journal reports.
Therapies aimed at drug targets that have been linked genetically to disease fare better through the drug development pipeline, researchers from GSK and elsewhere found.
The institute will develop new technologies and approaches to decode how genes are controlled and how a cell's "operating system" functions.
Originally published Oct. 3.
NEW YORK (GenomeWeb) – A team led by researchers at Cellzome, a part of GlaxoSmithKline's R&D division, has developed a thermal profiling-based method for identifying protein drug targets and measuring protein-drug binding.
New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.
A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.